A Phase 1, First-in-Human Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

A Phase 1, First-in-Human Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Conditions: Solid Tumor; Solid Tumor, Adult; Advanced Solid Tumor; Metastatic Tumor; Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinoma; Metastatic Ovarian Carcinoma; Endometrial Cancer; Endometrial Neoplasms; Endometrial Diseases; Metastatic Endometrial Cancer; Metastatic Endometrial Carcinoma; Advanced Endometrial Carcinoma; Advanced Ovarian Carcinoma; Gastric Cancer; Advanced Gastric Carcinoma; Metastatic Gastric Cancer; Metastatic Gastric Carcinoma; Small-cell Lung Cancer; Small Cell Lung Carcinoma; Triple Negative Breast Cancer; Triple Negative Breast Neoplasms; Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Carcinoma; CCNE1 Amplification; Hormone Receptor Negative Breast Carcinoma; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Progesterone-receptor-positive Breast Cancer
Interventions: Drug: NKT3447
Sponsors: NiKang Therapeutics, Inc.
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 20, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments